Interleukin-2 (IL-2) in the treatment of malignant brain tumors (glioblastomas).

摘要: The present study is aimed to provide a new possible approach the treatment of glioblastomas, in an effort control extremely severe evolution these tumors. Thus, from May 28, 1991, we started administration IL-2 (produced at "Victor Babes" Institute, Bucharest) 9 glioblastoma patients (operated on Neurosurgery department VII "G. Marinescu" Hospital, by repeated intraoperative and postoperative local injections. survival period first was 7 months (1 case), 8 (2 cases), 11 14 case) 17 case). There are only 2 survivors: one 4 other 23 following injection IL-2. survivor whose condition introduction therapy very good, demonstrates that offers some chance hopeless patients.